



UNIVERSITÀ
POLITECNICA
DELLE MARCHE

RESEARCH AREA: HEALTH - VIRUS - EPIDEMIOLOGY

TITLE: Hydroxychloroquine, dermatology and sars-cov-2: updating an old association

Principal investigator: Prof.ssa Annamaria Offidani, a.offidani@ospedlairiuniti.marche.it, tel: 071-5963574

UNIVPM Research Group: Clinica Dermatologica - Diotallevi Federico, Campanati Anna, Radi Giulia, Luchetti Michele Maria, Benfaremo Devis, Tagliati Corrado, Simonetti Oriana, Offidani Annamaria

Research activity description: Three months have passed since the World Health Organization (WHO) declared coronavirus disease 19 (COVID-19) as a pandemic on March 11, 2020.

Due to the high infection rates and occurrence of severe and fatal cases, the search for effective drugs to treat and control the COVID-19 pandemic has been prioritized by health and political authorities. Antimalarials, well-known for their use in dermatology and rheumatology, are one of the medications with the largest – albeit limited – scientific background warranting their use in the COVID-19 treatment protocols. Hydroxychloroquine (HCQ) has been used for the treatment of COVID-19 in 50 patients in our and other centres in several countries with encouraging results. However, recent studies disprove the real effectiveness of this drug, either alone or when combined with macrolides. As a result, the World Health Organization has discouraged the use of HCQ in the treatment and prevention of COVID-19. Herein we report our experience in the use of hydroxychloroquine for COVID-19 treatment. Herein we report our experience in the use of hydroxychloroquine for COVID-19 treatment.

Collaborators: Luchetti Michele Maria and Benfaremo Devis, Department of Medical and Surgical Sciences
